Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (symbol: VTGN) is a pioneering biotechnology firm committed to improving the lives of patients with central nervous system (CNS) disorders. The company leverages its advanced stem cell technology platform, which is based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed human cells. This innovative platform enables the creation of novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue, and cell therapy, providing clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
At the clinical stage, Vistagen is actively involved in developing and commercializing a robust pipeline consisting of six product candidates. Five of these candidates are clinical-stage investigational agents known as pherines, which represent a new class of drugs. Notable products within their portfolio include:
- PH94B: A novel neuroactive nasal spray designed to treat social anxiety disorder.
- PH10: An odorless, fast-acting synthetic neurosteroid aimed at addressing major depressive disorder (MDD).
- AV-101: An oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR), which is being developed to treat MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Vistagen's innovative approach and dedication to CNS disorders position it as a significant player in the biotechnology sector. The company is continually making strides in its research and clinical trials, striving to bring groundbreaking therapies to market. Investors and stakeholders can look forward to Vistagen's ongoing developments and potential future successes as it targets unmet medical needs with its cutting-edge technologies and therapeutic candidates.
VistaGen Therapeutics (NASDAQ: VTGN) appointed Maggie FitzPatrick to its Board of Directors, replacing Dr. Brian J. Underdown, who retired. FitzPatrick, a recognized corporate affairs expert, has extensive experience in healthcare marketing, previously working with companies like Johnson & Johnson and Cigna. Her public relations expertise is expected to benefit VistaGen as it progresses its CNS drug candidates. The company's focus remains on developing innovative therapies for anxiety and depression, with potential for significant market impact.
VistaGen Therapeutics (NASDAQ: VTGN) has announced its participation in the 'Updates in Neuropsych' panel at the William Blair Biotech Focus Conference 2021, scheduled for July 15, 2021, at 9:00 a.m. PT. The event aims to showcase advancements in the treatment of anxiety, depression, and other CNS disorders. VistaGen will also hold one-on-one meetings throughout the virtual conference. Interested parties can access the live webcast on the company’s website.
VistaGen Therapeutics (NASDAQ: VTGN) has appointed Mary L. Rotunno, J.D., to its Board of Directors. With over 30 years in healthcare and law, she aims to enhance the company’s strategies in mental health and wellness. Currently General Counsel at El Camino Health, Rotunno has a notable track record in governance and regulatory compliance. CEO Shawn Singh highlighted her insights as vital for VistaGen's upcoming corporate developments, specifically in advancing treatments for anxiety and depression disorders. This leadership change may strengthen VistaGen's position in the CNS market.
VistaGen Therapeutics (NASDAQ: VTGN) announced significant milestones in its corporate update and fiscal results for the year ended March 31, 2021. The company initiated the PALISADE-1 Phase 3 trial for PH94B, targeting rapid-onset treatment for social anxiety disorder (SAD), with topline data expected in mid-2022. VistaGen raised $127.5 million through partnerships and financing, enhancing its financial position. Notably, it formed a strategic agreement with EverInsight Therapeutics, securing $5 million upfront. The net loss decreased to $17.9 million, and cash reserves stood at $103.1 million as of March 31, 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced a corporate update conference call scheduled for June 29, 2021, at 2:00 PM PT. The call will disclose financial and operational results for the fiscal year ending March 31, 2021, and outline recent developments and future goals. CEO Shawn Singh will lead the call, which remains open to the public. A live audio webcast will also be accessible. This conference aims to inform shareholders and stakeholders about the company's progress in developing innovative treatments for CNS disorders.
VistaGen Therapeutics (NASDAQ: VTGN) announced its inclusion in the Russell 2000® Index effective June 28, 2021. This milestone is expected to enhance the company's visibility within the investment community, according to CEO Shawn K. Singh. The Russell 2000 Index is a widely recognized benchmark for small-cap companies, and its annual reconstitution considers approximately 4,000 U.S. stocks ranked by market capitalization. This move aims to introduce VistaGen to a broader investor audience as it advances its late-stage programs for anxiety and depression treatment.
VistaGen Therapeutics (NASDAQ: VTGN) has initiated its PALISADE-1 Phase 3 trial for PH94B, a nasal spray aimed at treating Social Anxiety Disorder (SAD). This randomized, double-blind, placebo-controlled study will assess the safety and efficacy of PH94B, which has received FDA Fast Track designation. The trial, involving 200 participants across 18 sites in the U.S., aims to confirm positive results seen in Phase 2 trials. Topline results are expected by mid-2022, with the potential to offer a rapid-acting treatment option for over 23 million Americans suffering from SAD.
VistaGen Therapeutics (NASDAQ: VTGN) announced its participation in two upcoming investor conferences in June 2021. The Jefferies Virtual Healthcare Conference will take place on June 2 at 2:30 p.m. ET, while the William Blair 41st Annual Virtual Growth Stock Conference is scheduled for June 3 at 3:00 p.m. ET. Both conferences will feature webcasts available for attendees. VistaGen focuses on developing innovative medications for anxiety, depression, and other CNS disorders. For more details, visit www.vistagen.com.
VistaGen Therapeutics has appointed Ann Cunningham as Chief Commercial Officer, enhancing its leadership team. With over 25 years of pharmaceutical experience, Cunningham has been involved in successful marketing strategies for neuropsychiatric products. Her expertise will support VistaGen's pre-commercial efforts for PH94B, aimed at treating social anxiety disorder. Cunningham's prior role on VistaGen's Board since January 2019 positions her well to drive brand awareness and market entry for the company’s CNS drug candidates. The transition reflects VistaGen's focus on expanding its commercial capabilities.
VistaGen Therapeutics (NASDAQ: VTGN) announced the appointment of Dr. Joanne Curley to its Board of Directors, expanding the board to seven members. With over 25 years of experience, including prior roles at Gilead Sciences and Vera Therapeutics, Dr. Curley has a track record of advancing multiple products through regulatory approvals. Her expertise in drug development aligns with VistaGen's mission to innovate treatments for anxiety and depression, enhancing leadership and strategic direction.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
What does Vistagen Therapeutics, Inc. specialize in?
What is the company's main technological focus?
What are pherines?
Can you name some of Vistagen Therapeutics' key products?
What is PH94B used for?
What is PH10?
What conditions is AV-101 aimed at treating?
How does Vistagen's stem cell technology benefit drug development?
Is Vistagen Therapeutics currently in the clinical stage?
Where can I find the latest news about Vistagen Therapeutics, Inc.?
